Evidence map›Paper›PMID 32348473›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance.

Fernanda Maruri, Yan Guo, Amondrea Blackman, Yuri F van der Heijden, Peter F Rebeiro, Timothy R Sterling

Open access · greenAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. RNA editing in Mycobacterium tuberculosis.Microbiological research · 2022
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Fernanda MaruriDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.ORCID 0000-0001-9533-8239
Yan GuoDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
Amondrea BlackmanDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Yuri F van der HeijdenDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Peter F RebeiroDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Timothy R SterlingDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Vanderbilt University · USUniversity of New Mexico · US

Funding

Fluoroquinolone Resistance in M. TuberculosisR01AI063200 · NIAID · VANDERBILT UNIVERSITY · PI STERLING, TIMOTHY R · 2006 to 2010
$1.8M
Fluoroquinolone resistance in patients with multidrug-resistant tuberculosisK08AI106420 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI VAN DER HEIJDEN, YURI F. · 2014 to 2018
$848k
Fluoroquinolones and Efflux-Mediated Cross Resistance in HIV-related TBR56AI118361 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SHERMAN, DAVID R, STERLING, TIMOTHY R · 2016 to 2016
$696k
The HIV Care Continuum and Health Policy: Changes through Context and GeographyK01AI131895 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI REBEIRO, PETER F · 2017 to 2021
$623k
NIAID NIH HHS K01 AI131895NIAID NIH HHS K08 AI106420NIAID NIH HHS R01 AI063200NIAID NIH HHS R56 AI118361
6 · The paper itself

Abstract

backgroundFluoroquinolone resistance in Mycobacterium tuberculosis (Mtb) is conferred by DNA gyrase mutations, but not all fluoroquinolone-resistant Mtb isolates have mutations detected. The optimal allele frequency threshold to identify resistance-conferring mutations by whole-genome sequencing is unknown.

methodsPhenotypically ofloxacin-resistant and lineage-matched ofloxacin-susceptible Mtb isolates underwent whole-genome sequencing at an average coverage depth of 868 reads. Polymorphisms within the quinolone-resistance-determining region (QRDR) of gyrA and gyrB were identified. The allele frequency threshold using the Genome Analysis Toolkit pipeline was ~8%; allele-level data identified the predominant variant allele frequency and mutational burden (ie, sum of all variant allele frequencies in the QRDR) in gyrA, gyrB, and gyrA + gyrB for each isolate. Receiver operating characteristic (ROC) curves assessed the optimal measure of allele frequency and potential thresholds for identifying phenotypically resistant isolates.

resultsOf 42 ofloxacin-resistant Mtb isolates, area under the ROC curve (AUC) was highest for predominant variant allele frequency, so that measure was used to evaluate optimal mutation detection thresholds. AUCs for 8%, 2.5%, and 0.8% thresholds were 0.8452, 0.9286, and 0.9069, respectively. Sensitivity and specificity were 69% and 100% for 8%, 86% and 100% for 2.5%, 91% and 91% for 0.8%. The sensitivity of the 2.5% and 0.8% thresholds were significantly higher than the 8% threshold (P = .016 and .004, respectively) but not significantly different between one another (P = .5).

conclusionsA predominant mutation allele frequency threshold of 2.5% had the highest AUC for detecting DNA gyrase mutations that confer ofloxacin resistance, and was therefore the optimal threshold.

Indexed as

Drug Resistance, BacterialMycobacterium tuberculosisAntitubercular AgentsDNA GyraseFluoroquinolonesMicrobial Sensitivity TestsMutationOfloxacinAntitubercular AgentsDNA GyraseFluoroquinolonesOfloxacinfluoroquinolone resistanceM. tuberculosiswhole-genome sequencing

Identifiers

PMID32348473
PMCPMC8315129
OpenAlexW3019186697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.